Trial reportInvestigational new drugs2011
Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortium.
Trial report in Investigational new drugs, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 60 citations in OpenAlex.
- Incidence of fatigue and low-dose corticosteroid use in prostate cancer patients receiving systemic treatment: a meta-analysis of randomized controlled trials.World journal of urology · 2019Pooled it
- Phase II study of cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium.Investigational new drugs · 2012Trial
- Deciphering the Tumor Microenvironment in Prostate Cancer: A Focus on the Stromal Component.Cancers · 2024Review
- TGF-β signaling in health, disease, and therapeutics.Signal transduction and targeted therapy · 2024Review
- Targeting TGFβ signal transduction for cancer therapy.Signal transduction and targeted therapy · 2021Review
- Position of Circulating Tumor Cells in the Clinical Routine in Prostate Cancer and Breast Cancer Patients.Cancers · 2020Review
- Aberrant integrin αv and α5 expression in prostate adenocarcinomas and bone-metastases is consistent with a bone-colonizing phenotype.Translational andrology and urology · 2020Article
- Involvement of Integrin-Activating Peptides Derived from Tenascin-C in Cancer Aggression and New Anticancer Strategy Using the Fibronectin-Derived Integrin-Inactivating Peptide.Molecules (Basel, Switzerland) · 2020Review
- Cell Adhesion Molecules and Their Roles and Regulation in the Immune and Tumor Microenvironment.Frontiers in immunology · 2019Review
- Integrin Inhibitors in Prostate Cancer.Cancers · 2018Review
- Proteolytic fragments of fibronectin function as matrikines driving the chemotactic affinity of prostate cancer cells to human bone marrow mesenchymal stromal cells via the α5β1 integrin.Cell adhesion & migration · 2017Article
- Peptides and peptidomimetics as regulators of protein-protein interactions.Current opinion in structural biology · 2017Review
- Systemic Delivery of Tumor-Targeted Bax-Derived Membrane-Active Peptides for the Treatment of Melanoma Tumors in a Humanized SCID Mouse Model.Molecular therapy : the journal of the American Society of Gene Therapy · 2017Article
- α3β1 Integrin Suppresses Prostate Cancer Metastasis via Regulation of the Hippo Pathway.Cancer research · 2016Article
- Access to site-specific Fc-cRGD peptide conjugates through streamlined expressed protein ligation.Organic & biomolecular chemistry · 2016Article
- Non-invasive assessment of inter-and intrapatient variability of integrin expression in metastasized prostate cancer by PET.Oncotarget · 2016Article
- In vitro and in vivo drug disposition of cilengitide in animals and human.Pharmacology research & perspectives · 2016Article
- Antiangiogenic mechanisms and factors in breast cancer treatment.Journal of carcinogenesis · 2016Review
- The effect of cilengitide in combination with irradiation and chemotherapy in head and neck squamous cell carcinoma cell lines.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2014Article
- Investigation of the essential role of platelet-tumor cell interactions in metastasis progression using an agent-based model.Theoretical biology & medical modelling · 2014Article
Corrections and comments
- Erratum issuedCooney, Kathleen A [added]; Mathew, Paul [added]; Pienta, Kenneth J [added]; Escara-Wilke, June [added]; Doyle, Gerald [added]; Al-Hawary, Mahmoud [added]; Keller, Evan T [added]
Authors and funding
17 authors at 5 institutions in 1 country.
Funding
Abstract
backgroundIntegrins are involved in prostate cancer metastasis by regulating cell adhesion, migration, invasion, motility, angiogenesis and bone metabolism. We evaluated the efficacy of two dose levels of cilengitide in patients (pts) with castrate resistant prostate cancer (CRPC).
methodsChemotherapy-naïve, asymptomatic metastatic CRPC pts were randomized to cilengitide 500 mg or 2,000 mg IV twice weekly using parallel 2-stage design. The primary endpoint was rate of objective clinical progression at 6-months. Secondary endpoints included clinical and PSA response rates, safety and effects of cilengitide treatment on circulating tumor cells (CTCs) and bone remodeling markers.
resultsForty-four pts were accrued to first stage (22/arm). Median number of cycles was three in both arms (500 mg arm: 1-8; 2,000 mg arm: 1-15). At 6 months, two pts (9%) on the 500 mg arm and five pts (23%) on the 2,000 mg arm had not progressed. Best objective response was stable disease (SD) in seven pts for 9.9[8.1,20.9] months. There were three grade 3 and no grade 4 toxicities. At 12 weeks, analysis of bone markers did not reveal significant trends. At progression, bone specific alkaline phosphatase and N-telopeptide increased in all pts, less so in pts on the 2,000 mg arm and in pts on both arms who obtained SD at 6 months. CTCs increased over time in both arms.
conclusionCilengitide was well tolerated with modest clinical effect in favor of the higher dose. The unique trial design including a shift from response rate to objective progression as the endpoint, and not acting on PSA increases was feasible.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.